Hongtao W. Duan

1 Xinsi Road
Xi'an, 710038, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 81 publications

Correction: Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma.

Correction: Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma.

Journal: BMC cancer

Published: August 01, 2026

Substantial but highly variable diffusive methane emissions from eutrophic shallow lakes.

Substantial but highly variable diffusive methane emissions from eutrophic shallow lakes.

Journal: Water research

Published: May 19, 2026

TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy.

TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy.

Journal: Cancer communications (London, England)

Published: December 21, 2025

Long-term observations uncover sustained carbon dioxide emissions from lakes following aquaculture retreat.

Long-term observations uncover sustained carbon dioxide emissions from lakes following aquaculture retreat.

Journal: Water research

Published: December 19, 2025

The effects of neoadjuvant sintilimab versus pembrolizumab combined with chemotherapy on resectable non-small cell lung cancer: a multicenter propensity score-matched study.

The effects of neoadjuvant sintilimab versus pembrolizumab combined with chemotherapy on resectable non-small cell lung cancer: a multicenter propensity score-matched study.

Journal: Translational lung cancer research

Published: November 05, 2025

Comparison of efficacy and surgery-related safety of perioperative tislelizumab and pembrolizumab with neoadjuvant chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study.

Comparison of efficacy and surgery-related safety of perioperative tislelizumab and pembrolizumab with neoadjuvant chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study.

Journal: Translational lung cancer research

Published: September 19, 2025

Effects of α-ketoglutarate and its calcium salt on growth performance, health, rumen fermentation and microbiota in fattening Hu lambs.

Effects of α-ketoglutarate and its calcium salt on growth performance, health, rumen fermentation and microbiota in fattening Hu lambs.

Journal: Animal : an international journal of animal bioscience

Published: September 11, 2025

Long-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Long-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: September 04, 2025

Correction: High Resolution Water Quality Dataset of Chinese Lakes and Reservoirs from 2000 to 2023.

Correction: High Resolution Water Quality Dataset of Chinese Lakes and Reservoirs from 2000 to 2023.

Journal: Scientific data

Published: June 30, 2025

Two vs three cycles of neoadjuvant immunochemotherapy for resectable non-small-cell lung cancer: a real-world population-based study.

Two vs three cycles of neoadjuvant immunochemotherapy for resectable non-small-cell lung cancer: a real-world population-based study.

Journal: Frontiers in immunology

Published: June 27, 2025

Three-Year Follow-Up of the Phase II Trial for Resectable Non-Small-Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD-NeoFOUR Trial.

Three-Year Follow-Up of the Phase II Trial for Resectable Non-Small-Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD-NeoFOUR Trial.

Journal: Thoracic cancer

Published: May 21, 2025

Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma.

Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma.

Journal: BMC cancer

Published: May 18, 2025

Showing 1-12 of 81

Last Updated: 09/26/2026